Literature DB >> 21859337

Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection.

Vanessa P Ho1, Stephen G Jenkins, Cheguevara I Afaneh, Harma K Turbendian, David P Nicolau, Philip S Barie.   

Abstract

BACKGROUND: Gram-negative bacterial resistance to antibiotics is of increasing concern. Carbapenem resistance among strains of Klebsiella pneumoniae is a relatively new phenomenon. Resistance attributable to production of carbapenemases is notoriously difficult to combat.
METHODS: Case report and review of the pertinent English-language literature.
RESULTS: A patient, hospitalized for aortic dissection complicated by intra-abdominal catastrophe and acute kidney injury, developed bacteremia exhibiting meropenem non-susceptibility secondary to expression of bla(KPC-2). High-dose, continuous-infusion meropenem achieved serum drug concentrations above the minimum inhibitory concentration and eradicated the infection.
CONCLUSION: This is the first report of a meropenem-non-susceptible carbapenamase-positive Klebsiella pneumoniae blood stream infection treated successfully with high-dose, continuous-infusion meropenem. Application of this regimen in certain patients, such as those with mild-to-moderate renal insufficiency, may be a reasonable option for multi-drug-resistant nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859337     DOI: 10.1089/sur.2010.072

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  8 in total

1.  Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach.

Authors:  Federico Pea; Pierluigi Viale; Piergiorgio Cojutti; Mario Furlanut
Journal:  Antimicrob Agents Chemother       Date:  2012-10-08       Impact factor: 5.191

2.  Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.

Authors:  Ryan K Shields; M Hong Nguyen; Brian A Potoski; Ellen G Press; Liang Chen; Barry N Kreiswirth; Lloyd G Clarke; Gregory A Eschenauer; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

3.  Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae.

Authors:  Asma Khatri; Nina Naeger Murphy; Peter Wiest; Melissa Osborn; Kathleen Garber; Michelle Hecker; Kelly Hurless; Susan D Rudin; Michael R Jacobs; Robert C Kalayjian; Robert A Salata; David van Duin; Federico Perez; Robert A Bonomo; David L Paterson; Patrick N A Harris
Journal:  Antimicrob Agents Chemother       Date:  2015-08       Impact factor: 5.191

Review 4.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

5.  Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.

Authors:  Piergiorgio Cojutti; Assunta Sartor; Elda Righi; Claudio Scarparo; Matteo Bassetti; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 6.  Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.

Authors:  Grace C Lee; David S Burgess
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-12-13       Impact factor: 3.944

Review 7.  Optimizing antimicrobial therapy in critically ill patients.

Authors:  Virginie Vitrat; Serge Hautefeuille; Cécile Janssen; David Bougon; Michel Sirodot; Leonardo Pagani
Journal:  Infect Drug Resist       Date:  2014-10-20       Impact factor: 4.003

Review 8.  Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens.

Authors:  Chang-Seop Lee; Yohei Doi
Journal:  Infect Chemother       Date:  2014-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.